Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents
Abstract
Neonatal sepsis is one of the most fulminating conditions in neonatal intensive care units. Antipathogen and supportive care are administered routinely, but do not deliver satisfactory results. In addition, the efforts to treat neonatal sepsis with anti-inflammatory agents have generally shown to be futile. The accumulating data imply that intracellular redox changes intertwined into neonatal sepsis redox cycle represent the main cause of dysfunction of mitochondria and cells in neonatal sepsis. Our aim here is to support the new philosophy in neonatal sepsis treatment, which involves the integration of mechanisms that are responsible for cellular dysfunction and organ failure, the recognition of the most important targets, and the selection of safe agents that can stop the neonatal sepsis redox cycle by hitting the hot spots. Redox-active agents that could be beneficial for neonatal sepsis treatment according to these criteria include lactoferrin, interleukin 10, zinc and selenium sup...plements, ibuprofen, edaravone, and pentoxifylline.
Keywords:
Antioxidants / mitochondria / neonate / oxidative stress / sepsisSource:
Shock, 2014, 42, 3, 179-184Publisher:
- Lippincott Williams & Wilkins, Philadelphia
Funding / projects:
- Molecular mechanisms of redox signalling in homeostasis: adaptation and pathology (RS-MESTD-Basic Research (BR or ON)-173014)
- Simultaneous Bioremediation and Soilification of Degraded Areas to Preserve Natural Resources of Biologically Active Substances, and Development and Production of Biomaterials and Dietetic Products (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-43004)
DOI: 10.1097/SHK.0000000000000198
ISSN: 1073-2322
PubMed: 24827393
WoS: 000341494400002
Scopus: 2-s2.0-85027930403
URI
https://cer.ihtm.bg.ac.rs/handle/123456789/1433https://journals.lww.com/shockjournal/Fulltext/2014/09000/Redox_Therapy_in_Neonatal_Sepsis___Reasons,.2.aspx#pdf-link
Collections
Institution/Community
IHTMTY - JOUR AU - Bajcetic, Milica AU - Spasić, Snežana AU - Spasojević, Ivan PY - 2014 UR - https://cer.ihtm.bg.ac.rs/handle/123456789/1433 UR - https://journals.lww.com/shockjournal/Fulltext/2014/09000/Redox_Therapy_in_Neonatal_Sepsis___Reasons,.2.aspx#pdf-link AB - Neonatal sepsis is one of the most fulminating conditions in neonatal intensive care units. Antipathogen and supportive care are administered routinely, but do not deliver satisfactory results. In addition, the efforts to treat neonatal sepsis with anti-inflammatory agents have generally shown to be futile. The accumulating data imply that intracellular redox changes intertwined into neonatal sepsis redox cycle represent the main cause of dysfunction of mitochondria and cells in neonatal sepsis. Our aim here is to support the new philosophy in neonatal sepsis treatment, which involves the integration of mechanisms that are responsible for cellular dysfunction and organ failure, the recognition of the most important targets, and the selection of safe agents that can stop the neonatal sepsis redox cycle by hitting the hot spots. Redox-active agents that could be beneficial for neonatal sepsis treatment according to these criteria include lactoferrin, interleukin 10, zinc and selenium supplements, ibuprofen, edaravone, and pentoxifylline. PB - Lippincott Williams & Wilkins, Philadelphia T2 - Shock T1 - Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents VL - 42 IS - 3 SP - 179 EP - 184 DO - 10.1097/SHK.0000000000000198 ER -
@article{ author = "Bajcetic, Milica and Spasić, Snežana and Spasojević, Ivan", year = "2014", abstract = "Neonatal sepsis is one of the most fulminating conditions in neonatal intensive care units. Antipathogen and supportive care are administered routinely, but do not deliver satisfactory results. In addition, the efforts to treat neonatal sepsis with anti-inflammatory agents have generally shown to be futile. The accumulating data imply that intracellular redox changes intertwined into neonatal sepsis redox cycle represent the main cause of dysfunction of mitochondria and cells in neonatal sepsis. Our aim here is to support the new philosophy in neonatal sepsis treatment, which involves the integration of mechanisms that are responsible for cellular dysfunction and organ failure, the recognition of the most important targets, and the selection of safe agents that can stop the neonatal sepsis redox cycle by hitting the hot spots. Redox-active agents that could be beneficial for neonatal sepsis treatment according to these criteria include lactoferrin, interleukin 10, zinc and selenium supplements, ibuprofen, edaravone, and pentoxifylline.", publisher = "Lippincott Williams & Wilkins, Philadelphia", journal = "Shock", title = "Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents", volume = "42", number = "3", pages = "179-184", doi = "10.1097/SHK.0000000000000198" }
Bajcetic, M., Spasić, S.,& Spasojević, I.. (2014). Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. in Shock Lippincott Williams & Wilkins, Philadelphia., 42(3), 179-184. https://doi.org/10.1097/SHK.0000000000000198
Bajcetic M, Spasić S, Spasojević I. Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. in Shock. 2014;42(3):179-184. doi:10.1097/SHK.0000000000000198 .
Bajcetic, Milica, Spasić, Snežana, Spasojević, Ivan, "Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents" in Shock, 42, no. 3 (2014):179-184, https://doi.org/10.1097/SHK.0000000000000198 . .